Nexalin Technology Secures Exclusive Distribution Agreement With Carmi Masha in Israel

Reuters2025-11-13
Nexalin Technology Secures Exclusive Distribution Agreement With Carmi Masha in Israel

Nexalin Technology Inc. has announced the appointment of Carmi Masha Technologies Ltd. as the exclusive distributor for its Gen-2 SYNC device in Israel. This follows the recent approval by the Israeli Ministry of Health, allowing commercial sales of the device for the treatment of mental health disorders such as insomnia, depression, and anxiety. Under the agreement, Carmi Masha Technologies will handle sales, marketing, clinical education, importation, registration, and distribution of the SYNC device throughout hospitals, clinics, and private treatment centers in Israel. The companies also plan to explore future applications for the technology in areas including PTSD, traumatic brain injury, and Alzheimer's disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574782-en) on November 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment